VITAFOL-OB + DHA Rx
Generic Name and Formulations:
Vit.A (as beta carotene) 2700 IU, thiamine 1.6mg, riboflavin 1.8mg, niacinamide 18mg, pyridoxine 2.5mg, folic acid 1mg, Vit.B12 12mcg, Vit.C 70mg, Vit.D 400 IU, Vit.E 30 IU, calcium (as carbonate) 100mg, copper (as oxide) 2mg, iron (as ferrous fumarate) 65mg, magnesium (as oxide) 25mg, zinc (as oxide) 25mg; caplets; gluten-, lactose-, iodine-, sugar-free. Docosahexaenoic acid (DHA) 250mg; gel caps; orange flavor.
Indications for VITAFOL-OB + DHA:
Nutritional supplement in pregnancy, prenatal, and postnatal periods.
1 caplet + 1 gel cap daily.
Pernicious anemia. Hemochromatosis. Iron storage disease. Chronic hemolytic anemia. Pyridoxine responsive anemia. Liver cirrhosis.
Folic acid may mask pernicious anemia. Overactive thyroid. Hypercalcemia. Hyperparathyroidism. Soy allergy. DHA: bleeding diatheses.
Iron, calcium block tetracycline absorption. Iodine with anti-thyroid drugs may cause hypothyroidism. Iodine with antihypertensives may increase potassium. Folic acid antagonizes methotrexate, anticonvulsants (eg, carbamazepine, fosphenytoin, phenytoin, phenobarbital, valproic acid). Separate dosing of zinc with antibiotics at least 2hrs apart. DHA: avoid anticoagulants.
GI upset, skin ailments, glucose abnormalities, visual problems.
Caplets—100; Softgel caps—30;
DHA (6 blister cards [5 caplets + 5 gel caps])—30-day supply
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline